Royalty Pharma PLC RPRX
58.21
0.56
0.97%
as of 25 Sep
- Market cap
- $34.4B
- P/E
- 40.1×
Follow RPRX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
26.73 | 28.62 | 32.63 | 38.67 |
P/S ratio |
6.48 | 6.98 | 8.59 | 9.84 | |
P/FCF ratio |
4.44 | 4.72 | 17.53 | 19.05 | |
P/Operating CF |
21.69 | 20.08 | 29.17 | 34.26 | |
P/B ratio |
1.58 | 1.71 | 2.11 | 2.55 | |
Price to Tangible BV |
1.75 | 1.89 | 2.32 | 2.82 | |
EV/Sales |
9.88 | 10.48 | 12.01 | 13.04 | |
EV/EBITDA |
14.87 | 15.65 | 18.04 | 21.38 | |
EV/Operating CF |
9.66 | 10.01 | 11.22 | 11.11 | |
EV/FCF |
6.77 | 7.09 | 24.51 | 25.25 | |
Quick Ratio |
1.85 | 1.05 | 1.19 | 1.38 | |
Current Ratio |
3.48 | 2.40 | 2.66 | 2.80 | |
Net Debt/EBITDA |
18.32 | 20.93 | 14.60 | 57.16 | |
Debt/Assets |
46.24% | 45.62% | 45.20% | 45.22% | |
Debt/Equity |
0.93 | 0.92 | 0.90 | 0.92 | |
Asset Turnover |
0.13 | 0.13 | 0.13 | 0.13 | |
Operating CF/Net income |
2.44 | 3.92 | 2.44 | 40.73 | |
Capex/Depreciation |
(105.46) | 0.00 | (51.17) | (27.81) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.29% | 8.12% | 6.31% | 14.51% | |
Selling, General and Administrative Expense of Revenue |
19.49% | 26.41% | 25.29% | 24.01% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
11.96% | 20.22% | 19.35% | 15.88% | |
Graham Net Nets |
(0.52) | (0.50) | (0.40) | (0.33) | |
Graham Number |
25.72 | 26.20 | 27.43 | 26.78 | |
Earnings Yield |
3.74% | 3.49% | 3.06% | 2.59% | |
Free Cash Flow Yield |
22.53% | 21.18% | 5.71% | 5.25% | |
Revenue per Share |
1.41 | 1.45 | 1.44 | 1.51 | |
Operating CF per Share |
1.63 | 1.92 | 1.64 | 1.64 | |
Capex per Share |
(2.23) | 0.00 | (1.04) | (0.56) | |
Free Cash Flow per Share |
(0.60) | 1.92 | 0.61 | 1.07 | |
Cash per Share |
2.21 | 1.48 | 1.39 | 1.88 | |
Shareholders Equity per Share |
22.28 | 22.60 | 22.75 | 21.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.28 | 22.60 | 22.75 | 21.99 | |
Free Cash Flow |
(259.26) | 827.15 | 265.87 | 477.44 | |
Working Capital |
1,318.74 | 891.88 | 890.13 | 1,133.64 | |
Capital Expenditures |
(961.87) | — | (452.37) | (251.02) | |
Net Current Asset Value |
(7,876.88) | (8,377.75) | (8,452.77) | (8,269.49) | |
EV/EBIT |
15.16 | 15.98 | 18.45 | 21.88 | |
Capex to Sales |
1.58 | 0.00 | 0.72 | 0.37 | |
Net Profit Margin |
47.30% | 33.96% | 46.73% | 2.65% | |
Price to Operating Income |
9.94 | 10.65 | 13.19 | 16.51 | |
| Other line items | |||||
Average Receivables |
26.90 | 28.14 | 25.65 | 29.61 | |
Average Payables |
31.74 | 16.39 | 31.56 | 27.89 | |
Average Assets |
18,694.76 | 18,921.75 | 18,711.84 | 19,071.39 | |
Average Common Equity |
9,939.67 | 10,028.65 | 9,862.75 | 9,644.33 |
Columns are period end dates